Federal Register of Legislation - Australian Government

Primary content

PB 30 of 2014 Arrangements as made
This instrument amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (No. PB 116 of 2010) to delete one item and its relevant restriction text from Schedule 1, and adds two items and their relevant restriction text to Schedule 3.
Administered by: Health
Registered 29 Apr 2014
Tabling HistoryDate
Tabled HR13-May-2014
Tabled Senate14-May-2014
Date of repeal 02 May 2014
Repealed by Division 1 of Part 5A of the Legislative Instruments Act 2003

 

PB 30 of 2014

National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 4)

 

National Health Act 1953

___________________________________________________________________________

 

 

I, FELICITY MCNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the

National Health Act 1953.

Dated 19 April 2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FELICITY MCNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

 

 


1       Name of Instrument

 

(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No.4).

 

(2)                This Instrument may also be cited as PB 30 of 2014.

 

2              Commencement

This Instrument commences on 1 May 2014.

3              Amendments to PB 116 of 2010

Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).

 

 


Schedule 1       Amendments

 [1]     Schedule 1, entry for Atazanavir, in the form capsule 100 mg (as sulphate), brand name Reyataz

Omit

[2]      Schedule 1, after entry for Peginterferon Alfa-2a

Insert:

Plerixafor

Injection 24 mg in 1.2 mL

Injection

Mozobil

GZ

EMP

C4549 C4550

 

1

1

D

[3]      Schedule 1, after entry for Tenofovir with emtricitabine and efavirenz

Insert:

Tenofovir with emtricitabine, elvitegravir and cobicistat

Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg, elvitegravir 150 mg and cobicistat 150 mg

Oral

Stribild

GI

EMP

C4470 C4494 C4522 C4533

 

60

5

D

[4]      Schedule 3, after entry for Peginterferon Alfa-2a

Insert:

Plerixafor

C4549

 

Where the patient is receiving treatment at/from a public hospital

 

Mobilisation of haematopoietic stem cells

The treatment must be in combination with granulocyte-colony stimulating factor (G-CSF); AND
Patient must have lymphoma; OR
Patient must have multiple myeloma; AND
Patient must require autologous stem cell transplantation; AND
Patient must have failed previous stem cell collection; OR
Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per microlitre on the day of planned collection; OR
Patient must be undergoing chemotherapy plus G-CSF mobilisation and the first apheresis has yielded less than 1 million CD34+ cells/kg.


Evidence that the patient meets the PBS restriction criteria must be recorded in the patient's medical records

Compliance with Written and Telephone Authority Required procedures - Streamlined Authority Code 4549


 

 

C4550

 

Where the patient is receiving treatment at/from a private hospital

 

Mobilisation of haematopoietic stem cells

The treatment must be in combination with granulocyte-colony stimulating factor (G-CSF); AND

Patient must have lymphoma; OR

Patient must have multiple myeloma; AND

Patient must require autologous stem cell transplantation; AND

Patient must have failed previous stem cell collection; OR

Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per microlitre on the day of planned collection; OR

Patient must be undergoing chemotherapy plus G-CSF mobilisation and the first apheresis has yielded less than 1 million CD34+ cells/kg.

 

Evidence that the patient meets the PBS restriction criteria must be recorded in the patient's medical records.

Compliance with Written or Telephone Authority Required procedures


 

 

[5]      Schedule 3, after entry for Tenofovir with emtricitabine and efavirenz

Insert:

Tenofovir with emtricitabine, elvitegravir and cobicistat

C4470

 

Where the patient is receiving treatment at/from a public hospital

HIV infection

Continuing treatment

Patient must have previously received PBS-subsidised therapy for HIV infection.

Compliance with Written and Telephone Authority Required procedures - Streamlined Authority Code 4470

 

C4494

 

Where the patient is receiving treatment at/from a private hospital

HIV infection

Continuing treatment

Patient must have previously received PBS-subsidised therapy for HIV infection.

Compliance with Written or Telephone Authority Required procedures


 

C4522

 

Where the patient is receiving treatment at/from a public hospital

HIV infection

Initial treatment

Patient must be antiretroviral treatment naive.

Compliance with Written and Telephone Authority Required procedures - Streamlined Authority Code 4522

 

C4533

 

Where the patient is receiving treatment at/from a private hospital

HIV infection

Initial treatment

Patient must be antiretroviral treatment naive.

Compliance with Written and Telephone Authority Required procedures